Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) EPS (Basic) (2016 - 2025)

Iovance Biotherapeutics has reported EPS (Basic) over the past 13 years, most recently at -$0.15 for Q4 2025.

  • Quarterly results put EPS (Basic) at -$0.15 for Q4 2025, up 40.0% from a year ago — trailing twelve months through Dec 2025 was -$1.09 (up 15.5% YoY), and the annual figure for FY2025 was -$1.09, up 14.84%.
  • EPS (Basic) for Q4 2025 was -$0.15 at Iovance Biotherapeutics, up from -$0.25 in the prior quarter.
  • Over the last five years, EPS (Basic) for IOVA hit a ceiling of -$0.15 in Q4 2025 and a floor of -$0.5 in Q1 2023.
  • Median EPS (Basic) over the past 3 years was -$0.35 (2024), compared with a mean of -$0.36.
  • Biggest five-year swings in EPS (Basic): skyrocketed 44.44% in 2024 and later increased 2.94% in 2025.
  • Iovance Biotherapeutics' EPS (Basic) stood at -$0.45 in 2023, then skyrocketed by 44.44% to -$0.25 in 2024, then surged by 40.0% to -$0.15 in 2025.
  • The last three reported values for EPS (Basic) were -$0.15 (Q4 2025), -$0.25 (Q3 2025), and -$0.33 (Q2 2025) per Business Quant data.